Zhitong Financial App News, Maiwei Bio-B (02493) announced that at the 2026 European Respiratory Society Annual Meeting (ERS) to be held in Barcelona from September 5 to September 9, 2026, the company will announce 9mW1911 phase IB/IIa clinical study data on patients with moderate to severe COPD who have previously smoked in the form of a poster. Preliminary efficacy results show that 9MW1911 showed positive efficacy signals in reducing acute exacerbation of COPD in the middle to high dose group.

There is still uncertainty about whether clinical trial results can support the submission of marketing applications for the drug, whether it will finally be approved for marketing, and when it will be approved for marketing. Investors are kindly requested to pay attention to potential investment risks. The company will promptly fulfill its obligation to disclose information on subsequent developments in accordance with relevant regulations.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.